Search

everythinglearnresearchcommunity

for

Search:↓

The conversation is about acquiring GT20029 for hair loss treatment. The user is looking for information on how to obtain it.

The user has been using 1mg finasteride and 2.5mg oral minoxidil for three months, noticing new blonde hairs but experiencing ongoing shedding. They also use GHK-Cu, which has improved skin but not hair.

A user's personal hair loss progress with treatments, including finasteride (1.25mg), minoxidil, needling, and Nizoral; and advice from other users on how to perform the needling correctly.

GT20029 is a new hair loss treatment in Phase 3 trials in China, using PROTAC technology to target androgen receptors, potentially with fewer side effects than finasteride and minoxidil. VDPHL01, a second-generation minoxidil, is also mentioned as potentially more effective.

GT20029 showed significant hair growth and safety in phase II trials, with no adverse sexual events. Users are hopeful but concerned about future costs and systemic effects.

User shared 8-month progress with finasteride 0.5 mg 4 times a week and gluten-free diet for 5 months, improving hair loss. Plans to try microneedling soon.

The conversation discusses the potential of a new hair loss treatment, GT20029, which targets androgen receptors in the scalp and is in phase 1 trials in China. Users express hope that this treatment will be more effective than current options like Minoxidil and Finasteride.

The user is experiencing hair miniaturization despite using dutasteride 0.5mg daily and oral minoxidil 3mg daily for three months. They are advised to continue the treatment as full effects may take up to a year.

The conversation is about the anticipation of results for a hair loss treatment study, specifically for GT20029, with expectations for the results to be released in the first quarter of 2024. No specific treatments were discussed.

HMI-115 shows promising hair growth and thickening in just 2 months. Results are positive but need more time for confirmation.

The user has been using a chewable containing Finasteride, Minoxidil, and vitamins for nearly 5 months, noticing new baby hairs and increased dandruff. The chewables are from a company called Hims, and another user suggested a small hair transplant for better results.

A user started taking 1mg finasteride for hair loss and plans to follow a thrice-weekly dosing schedule recommended by two doctors. They previously used saw palmetto without issues and are hopeful finasteride won't cause sexual side effects.

The user is experiencing hair shedding after using minoxidil and is considering switching to dutasteride while planning to increase their oral minoxidil dose. They also use nicotine pouches, Vyvanse, and GHK-Cu, and have noticed thicker eyebrows and lashes from oral minoxidil.

A user shared impressive hair regrowth results after using 1mg finasteride daily for over a year, with minimal side effects. The user also mentioned taking biotin gummies and experiencing periods of shedding followed by thicker hair growth.

PP405 is likely fake, and JXL069 is an unrefined prototype with unknown side effects. It's advised to wait for the official PP405 release.

Scientists discovered a sugar gel, 2dDR-SA, that increased hair growth in mice. Users discussed its potential, comparing it to other treatments like Minoxidil and finasteride.

A user is seeking advice on sourcing finasteride from Spain or Turkey, considering cost and prescription requirements. In Turkey, Proscar 5 mg is available without a prescription for about $5 for 28 tablets.

Oral minoxidil can cause multiple facial hairs to grow from one follicle, known as Pili Multigemini, leading to ingrown hairs and zits. Users report increased facial and body hair growth, with some experiencing fewer issues after switching to dutasteride.

PP405 is a potential hair loss treatment showing promise, especially for men with severe balding. Some are hopeful it will be a game-changer for those who cannot tolerate finasteride or minoxidil, despite skepticism about the outcomes.

The conversation discusses a user's plan to inject NAD+ and GHK-Cu into their scalp to improve hair health, with concerns raised about the risks of infection and necrosis. Alternatives like finasteride, dutasteride, microneedling, oral minoxidil, and scalp massages are suggested.

The user has been using oral finasteride and minoxidil nightly, dutasteride twice a week, microneedling weekly, and pyripure nightly since April. They are seeking opinions on their hair regrowth progress, noting no slick bald areas but some miniaturized blonde hairs.

GT20029, a new hair loss treatment, shows promising results but only a slight improvement over placebo. People are cautiously optimistic, discussing its potential and combining it with existing treatments like Minoxidil and Finasteride.

Setipiprant trial for hair loss failed, showing no difference between placebo and treatment. Discussion also noted placebo users reporting side effects.

Setipiprant and Fevipiprant are questioned for their effectiveness in hair maintenance, with skepticism due to lack of convincing results beyond vellus hair growth. The user is satisfied with Minoxidil and Finasteride but is curious about the potential of DP2 inhibitors.

The conversation is about frustration over the delay in phase 2 results for a hair loss treatment called GT20029. One user suspects the treatment may have failed.

The conversation discusses hair loss treatments, specifically seeking a 15% glycyrrhizic acid formula without additional ingredients. It also mentions the potential opposite effects of glycyrrhizic acid on humans compared to rats.

Scientists discover SCUBE3 molecule for potential baldness cure. Mice used in research for hair growth signaling.

Emerging hair loss treatments like PP405, a topical MPC inhibitor, show promise in activating stem cells for hair growth. The conversation seeks information on the development stages and accessibility of these treatments.

The conversation discusses the use of Minoxidil and finasteride for hair loss and explores the potential of Geranium sibiricum extract as a safer alternative. It highlights the difficulty in finding this specific extract and suggests considering other plants with similar compounds, like Indian gooseberry.

The conversation discusses the availability of GT20029, a new topical hair loss treatment with fewer side effects than Minoxidil or finasteride. Users suggest using finasteride to preserve hair until GT20029 becomes available.